Clinical Edge Journal Scan

Pre-pregnancy migraine history not a significant risk factor for spontaneous abortion


 

Key clinical point: A preconception history of migraine showed no significant association with the risk for spontaneous abortion (SAB); however, routine use of medication, suggesting more severe migraine, may confer a greater SAB risk.

Major finding: Preconception migraine history did not increase the risk for SAB (adjusted hazard ratio [aHR] 1.03; 95% CI 0.91-1.16), but daily migraine medication use (aHR 1.38; 95% CI 0.81-2.35), use of prescription migraine prophylaxis medication (aHR 1.43; 95% CI 0.72-2.84), or analgesic/caffeine medication use (aHR 1.42; 95% CI 0.99-2.04) showed a modest but non-significant association with SAB risk.

Study details: This study evaluated 7890 participants from an ongoing prospective study who conceived during follow-up and had or did not have a preconception diagnosis of migraine or migraine medication use, of which 1537 experienced SAB.

Disclosures: This study was funded by the National Institute of Child Health and Human Development, US National Institutes of Health. The authors declared no conflicts of interest.

Source: Crowe HM et al. Pre pregnancy migraine diagnosis, medication use, and spontaneous abortion: A prospective cohort study. J Headache Pain. 2022;23:162 (Dec 20). Doi: 10.1186/s10194-022-01533-6

Recommended Reading

Migraine: A significant risk factor for cardiovascular diseases
Migraine ICYMI
Cluster headache tied to high risk of mental and neurologic disorders
Migraine ICYMI
Commentary: Research on Potential Migraine Triggers, January 2023
Migraine ICYMI
Medication Overuse Headache (MOH): Prevention and Treatment
Migraine ICYMI
Dietary zinc seen reducing migraine risk
Migraine ICYMI
Remote electrical neuromodulation device helps reduce migraine days
Migraine ICYMI
Persistent post-traumatic and new daily persistent headache may indicate abrupt migraine onset
Migraine ICYMI
Chronic migraine: No synergistic effect with erenumab-onabotulinumtoxinA dual therapy
Migraine ICYMI
Chronic migraine: No synergistic effect with erenumab-onabotulinumtoxinA dual therapy
Migraine ICYMI
No benefits of supportive self-management program in chronic migraine
Migraine ICYMI